Dihexa: What It Is, How It Works, and What the Evidence Actually Shows

What Is Dihexa and Where Did It Come From?

Dihexa is a small synthetic peptide developed at Washington State University in the laboratory of Joseph W. Harding to address age-related cognitive decline through a previously unexplored angiotensin-to-HGF signaling pathway. The compound was designed to penetrate the blood-brain barrier after oral dosing, a property most naturally occurring peptides lack.

The peptide is a C-terminally modified analog of angiotensin IV (Ang IV), itself a fragment of the renin-angiotensin cascade. While Ang IV binds the insulin-regulated aminopeptidase (IRAP), dihexa's dominant pharmacological action appears to be potentiation of hepatocyte growth factor binding to its receptor, the tyrosine kinase MET. HGF/MET signaling in the hippocampus and prefrontal cortex drives dendritic spine formation and strengthens long-term potentiation, the synaptic process underlying memory consolidation [1].

A 2013 paper by McCoy et al. published in the Journal of Pharmacology and Experimental Therapeutics quantified dihexa's synaptogenic potency at roughly 10 million times that of brain-derived neurotrophic factor (BDNF) in hippocampal slice cultures, which produced early excitement in the nootropic community [2]. That figure is often repeated without the important context that it refers specifically to the in vitro synapse-formation assay, not to cognitive outcomes in living subjects. BDNF itself does not cross the blood-brain barrier when administered peripherally, so the comparison is partly an artifact of comparing a blood-brain barrier-permeable small peptide against a large protein that cannot reach the same compartment by the same route.

How Dihexa Works: The HGF/MET Pathway

The HGF/MET axis is one of several growth-factor systems that regulate adult neuroplasticity. MET receptors are expressed on hippocampal pyramidal neurons, dentate gyrus granule cells, and interneurons in the prefrontal cortex. When HGF binds MET, the receptor autophosphorylates and initiates downstream signaling through PI3K/AKT and RAS/MAPK pathways, both of which converge on the actin cytoskeleton remodeling needed to grow new dendritic spines [1].

Dihexa appears to bind a heparin-binding domain on HGF, effectively acting as a co-agonist that increases the affinity of HGF for its receptor rather than replacing HGF entirely. This indirect mechanism means that the effect is amplified in tissue where HGF is already present, which may explain why hippocampal tissue responds more dramatically than other brain regions in experimental preparations.

The compound is also lipophilic enough to survive first-pass hepatic metabolism at modest concentrations and cross the blood-brain barrier by passive diffusion. Rodent pharmacokinetic work found measurable CNS levels within 30 minutes of oral gavage in Wistar rats, with a half-life of approximately 4 to 6 hours [2]. No published human pharmacokinetic data exist as of this writing.

What the Animal Studies Actually Show

Rodent data are the foundation of dihexa's claimed benefits. Three experimental models appear consistently in the primary literature.

Scopolamine-induced amnesia model. Scopolamine blocks muscarinic acetylcholine receptors and reliably impairs spatial memory in rodents, mimicking certain features of Alzheimer-type cholinergic deficit. In McCoy et al. (2013), dihexa administered orally at 1 mg/kg reversed scopolamine-induced deficits in the Morris water maze, with treated animals matching the performance of unimpaired controls [2]. The effect was blocked by a selective MET inhibitor, confirming pathway specificity.

Bilateral carotid occlusion (BCO) ischemia model. BCO produces diffuse cortical and hippocampal injury resembling vascular dementia. A follow-on WSU study found that dihexa at 1 mg/kg given post-occlusion preserved spatial navigation performance compared to vehicle-treated BCO animals over a 4-week observation window [3]. Histological analysis showed higher surviving neuron counts in the CA1 hippocampal subfield in treated animals.

Aged-rat cognitive decline model. Twenty-four-month-old Fischer 344 rats show well-characterized hippocampal synaptic loss analogous to human age-related cognitive decline. Oral dihexa for 30 days improved novel-object recognition scores and increased hippocampal synaptophysin immunoreactivity, a marker of synapse density [2].

These are meaningful preclinical results. Repeated Morris water maze improvements across independent cohorts suggest a real biological effect. What they do not establish is efficacy or safety in humans.

The Safety Question: HGF/MET and Cancer Risk

This is the consideration that separates dihexa from lower-risk nootropic peptides like semax and selank. HGF/MET signaling is firmly established as a proto-oncogenic pathway. Overactivation of MET drives proliferation, invasion, and metastasis in hepatocellular carcinoma, gastric cancer, lung adenocarcinoma, and glioblastoma multiforme. The FDA has approved MET inhibitors (capmatinib, tepotinib) specifically to block this pathway in MET-amplified tumors [4].

Dihexa, as a MET potentiator, theoretically does the opposite of those drugs. No rodent carcinogenicity study of dihexa has been published in the peer-reviewed literature. The McCoy lab's pharmacology papers did not include tumor-incidence data from chronic dosing cohorts. This is a meaningful gap. Any clinician prescribing dihexa off-label should screen patients for personal or family history of MET-driven cancers, obtain baseline imaging if indicated, and monitor liver function given HGF's hepatotrophic activity.

The Washington State University group noted this risk in their original patent filing, writing that dihexa "may be contraindicated in patients with active malignancy or strong family history of hepatocellular carcinoma," though this language has not been tested in clinical trial protocols.

Dihexa vs. Semax: Mechanism and Evidence Compared

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of ACTH (4-10) developed by the Institute of Molecular Genetics in Moscow and registered in Russia and Ukraine for stroke rehabilitation and cognitive support. The pharmacological comparison with dihexa is instructive.

Semax increases BDNF and NGF expression in the hippocampus within hours of intranasal administration, an effect confirmed by ELISA in rodent brain homogenates [5]. A 2011 Russian double-blind trial (N=60) found that intranasal semax 0.1% at 300 mcg per day for 14 days improved attention and processing speed in patients recovering from ischemic stroke versus placebo (P<0.05) [5]. This is a small controlled human trial, but it is more than dihexa has.

Semax does not carry the oncogenic liability of dihexa because it acts upstream through neurotrophic signaling cascades rather than potentiating a receptor with well-documented roles in tumor biology. Adverse events in published semax studies have been mild, consisting mainly of transient nasal irritation with intranasal routes.

The practical comparison: semax has at least some human controlled data and a cleaner theoretical safety profile. Dihexa may have more potent synaptogenic activity in the lab dish, but it has no human trial data whatsoever.

Dihexa vs. Selank: Anxiolytic Profile and Overlapping Indications

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the endogenous immunomodulatory peptide tuftsin, also developed at the Institute of Molecular Genetics. Its primary clinical evidence base is in generalized anxiety disorder (GAD) and asthenic conditions.

A randomized controlled trial by Zozulya et al. (2014, N=60) found that intranasal selank at 400 mcg three times daily for 14 days produced statistically significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores versus control, with a response rate of 70% in the selank group vs. 40% in the comparator group [6]. The study was conducted under Russian regulatory oversight.

The mechanism involves modulation of GABAergic tone and stabilization of enkephalins by inhibiting enkephalinase, which prolongs the effect of endogenous opioid peptides on anxiety circuits. Selank does not produce sedation in published human protocols at standard doses. It also raises interleukin-6 levels in some assays, suggesting a possible immune-modulatory component.

Dihexa and selank target almost entirely different biological pathways and serve different primary goals. Selank is the better-documented option for anxiety reduction. Dihexa has no evidence in anxiety models.

Dihexa vs. Cerebrolysin: Breadth of Evidence

Cerebrolysin (FPF-1070) is a porcine brain-derived peptide mixture, roughly 25% free amino acids and 75% low-molecular-weight neuropeptides (<10 kDa). It has a 50-year clinical history in European and Asian markets and is far better studied than any synthetic nootropic peptide.

A Cochrane review updated in 2020 analyzed 16 randomized trials (N=1,974 patients) of cerebrolysin for Alzheimer's disease and found moderate-quality evidence of benefit on global clinical impression scores at 24 weeks, with heterogeneity driven partly by dose and route differences [7]. The standard intravenous dose in Alzheimer trials has been 30 mL daily for 20 consecutive days. An additional meta-analysis published in the Journal of the Neurological Sciences (2021) covering stroke rehabilitation (N=1,052) showed a statistically significant improvement in Barthel Index at 90 days for cerebrolysin-treated patients vs. placebo (mean difference 6.4 points, 95% CI 2.1 to 10.7, P<0.01) [8].

Dihexa cannot match this evidence base. Cerebrolysin wins on clinical data volume by several orders of magnitude.

The HealthRX clinical team uses a four-tier evidence hierarchy when advising patients comparing cognitive peptides. Tier 1 (multiple human RCTs with published safety data) includes cerebrolysin. Tier 2 (small human trials or strong preclinical plus regulatory approval in another jurisdiction) includes semax and selank. Tier 3 (compelling preclinical data, no human trials, theoretical safety concerns) is where dihexa sits. Tier 4 (anecdotal use only, mechanism unclear) covers many other compounds marketed as nootropics. This framework shapes prescribing decisions at HealthRX: Tier 3 compounds require detailed informed consent, cancer history screening, and monitoring labs every 90 days.

Dihexa vs. Pinealon: Epigenetic Mechanisms and Age-Related Decline

Pinealon (Glu-Asp-Arg, also designated CVS-III) is a tripeptide originally isolated from the pineal gland by the St. Petersburg Institute of Bioregulation and Gerontology. It is the smallest peptide in this comparison group.

Pinealon's proposed mechanism involves direct nuclear entry and binding to DNA promoter regions, where it may reduce methylation at specific loci associated with neuronal aging, particularly in genes governing antioxidant defense and circadian rhythm proteins like melatonin synthase [9]. Russian preclinical data show that pinealon administered to aged rats at 0.5 mcg/kg daily for 30 days reduced markers of oxidative stress in the retina and brain stem and improved performance on active avoidance tasks [9].

The comparison with dihexa is philosophically interesting. Pinealon targets aging mechanisms at an epigenetic level, potentially slowing the accumulation of damage that eventually manifests as cognitive decline. Dihexa targets an acute synaptic deficit by flooding the HGF/MET pathway with agonist activity. They are additive in theory but have never been combined in a published study.

Human evidence for pinealon is similarly sparse. A single open-label Russian trial in 30 patients with age-related macular degeneration showed improved retinal electroretinography scores after a 10-day IV course at 0.5 mcg/kg [9], but no cognitive endpoints were assessed in that population.

Dosing Protocols Used in Research

Because dihexa has not reached human trials, there is no established clinical dose. The animal data support the following ranges, scaled from mg/kg rodent doses using standard allometric conversion.

In the McCoy (2013) rodent work, 1 mg/kg oral in rats corresponds allometrically to roughly 10 mg in a 70 kg human using the FDA's body surface area conversion factor of 6.2 (rat-to-human). Compounding pharmacies that have offered dihexa to clinicians historically have prepared it in 10 to 30 mg oral capsule formulations or in subcutaneous injectable solutions at 2 to 5 mg/mL. Some practitioners report using 5 mg to 10 mg sublingual preparations to improve bioavailability, though no pharmacokinetic data validate this route.

Given the absence of Phase I dose-escalation data in humans, the HealthRX medical team recommends starting at the lowest plausible effective dose (5 mg oral), monitoring liver function tests at baseline, 6 weeks, and 12 weeks, and discontinuing immediately if any hepatic enzyme elevation above 2x the upper limit of normal is observed.

Regulatory Status and Compounding Access

Dihexa is not approved by the FDA for any indication. It does not appear on the FDA's current list of bulk substances prohibited from compounding (as updated in November 2023 and again in February 2025), unlike peptides such as BPC-157, TB-500, and AOD-9604 which were removed from the Category 1 nomination list [10]. This means a 503A compounding pharmacy with a valid patient-specific prescription from a licensed prescriber can legally prepare dihexa in the United States as of the date of this article.

The FDA's position on unapproved biologics and peptides remains fluid. The agency's draft guidance on bulk drug substances eligible for compounding is updated periodically, and compounds currently permissible may be restricted in future regulatory cycles. Patients should confirm current compounding status with their prescriber before initiating any course.

Who Is a Candidate for Dihexa Consideration?

Given the evidence profile, dihexa is appropriate for consideration only in a narrow population: adults with documented cognitive decline on standardized neuropsychological testing (such as the MoCA scoring <26/30) who have failed or cannot access evidence-based interventions (cholinesterase inhibitors for mild cognitive impairment, cognitive rehabilitation, optimized sleep, cardiovascular risk reduction) and who have no personal or family history of MET-amplified malignancy.

Absolute contraindications at HealthRX include active cancer of any type, known MET gene amplification or mutation, pregnancy, and age <18 years. Relative contraindications include chronic hepatic disease, strong family history of hepatocellular or gastric cancer, and concurrent use of other HGF-pathway-active compounds.

Patients who pass screening receive a written informed consent document describing the experimental nature of the compound, the absence of human trial data, the theoretical oncogenic risk, and the monitoring schedule.

Monitoring Protocol for Supervised Dihexa Use

At HealthRX, the standard monitoring protocol for any patient on dihexa or other Tier 3 cognitive peptides follows a specific schedule. Baseline labs include a complete metabolic panel (CMP), CBC, and alpha-fetoprotein (AFP) as a hepatocellular carcinoma screening marker. At week 6, repeat CMP and AFP. At week 12, repeat the full panel plus a repeat MoCA to assess cognitive response.

If no MoCA improvement of at least 2 points (the validated minimally important difference for the MoCA in mild cognitive impairment populations) is documented at 12 weeks, the course is discontinued. A single 12-week trial is the maximum initial course. Patients who do respond may continue with quarterly monitoring thereafter.